55504 Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group, Genetics 

of Health and Disease Study Section. 

Date: October 19–20, 2006. 

Time: 9 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Cheryl M. Corsaro, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2204, 

MSC 7890, Bethesda, MD 20892, (301) 435–

1045, corsaroc@csr.nih.gov. 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group, International and Cooperative 

Projects—1 Study Section. 

Date: October 20, 2006. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Doubletree Hotel, 1515 Rhode 

Island Avenue, NW., Washington, DC 20005. 

Contact Person: Manana Sukhareva, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3214, 

MSC 7808, Bethesda, MD 20892, 301–435–

1116, sukharem@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Community 

Level Health Promotion R21, R15 and R03’s. 

Date: October 20, 2006. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Fungai F. Chanetsa, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3135, 

MSC 7770, Bethesda, MD 20892, 301–435–

1262, chanetsaf@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Stress 

Biomarkers as Disease Risk Factors. 

Date: October 20, 2006. 

Time: 8:30 a.m. to 9:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Helix, 1430 Rhode Island 

Avenue, NW., Washington, DC 20005. 

Contact Person: Luci Roberts, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3188, 

MSC 7848, Bethesda, MD 20892, (301) 435–

0692, roberlu@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Heart 

Development and Vascular Remodeling. 

Date: October 20, 2006. 

Time: 9 a.m. to 10:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hotel and Corporate 

Quarters, 1615 Rhode Island Avenue, NW., 

Washington, DC 20036. 

Contact Person: Anshumali Chaudhari, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4124, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1210, chaudhaa@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Collaborative Applications in Child 

Psychopathology. 

Date: October 20, 2006. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Jane A. DoussardRoosevelt, PhD, Scientific Review 

Administrator, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3184, MSC 7848, Bethesda, MD 

20892, (301) 435–4445, doussarj@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 14, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8094 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Intercellular 

Interactions Study Section, October 3, 

2006, 8 a.m. to October 4, 2006, 6:30 

p.m., Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814 which 

was published in the Federal Register 

on September 7, 2006, 71 FR 52809–

52810. 

The meeting will be held at The 

Watergate, 2650 Virginia Avenue, NW., 

Washington, DC 20037. The meeting 

dates and time remain the same. The 

meeting is closed to the public. 

Dated: September 14, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8095 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Option to a 

Co-Exclusive License: Development of 

Antibody-Based Therapeutics That 

Specifically Bind the Platelet-Derived 

Growth Factor Receptor Alpha 

(CD140A/PDGFR2/PDGFRA) 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an option to 

a co-exclusive commercialization 

license to practice the inventions 

embodied in any or all of (a) U.S. 

patents 5,468,468 (11/21/1995); 

5,833,986 (11/10/1998); 5,863,739 (01/ 

26/1999); 5,965,359 (10/12/1999); 

6,228,600 (05/08/2001) and 6,660,488 

(12/09/2003), (b) U.S. patent 

applications 07/308,282 (02/09/1989, 

now abandoned), 07/915,884 (7/20/ 

1992, now abandoned), 08/439,095 (05/ 

11/1995, pending), 10/700,249 (11/03/ 

2003, pending) and (c) foreign 

applications corresponding to PCT 

Patent Application PCT/US90/00617 

entitled ‘‘Type Alpha Platelet Derived 

Growth Factor Receptor Gene’’, 

published as WO 90/10013 (9/7/1990) to 

AstraZeneca Pharmaceuticals LP having 

a principal place of business in Boston, 

MA. 

The prospective option to a coexclusive license will have a Licensed 

Territory which is worldwide. The 

prospective option to the co-exclusive 

license will have a Field of Use limited 

to the development of compositions and 

methods of utilizing antibody-based 

products that specifically bind the alpha 

platelet-derived growth factor receptor 

(a -PDGFR/CD140a/PDGFRA/PDGF2/ 

PDGFR-a), for the treatment of cancer 

and diagnostics specifically useful 

therewith. Only a single option to a coexclusive license will be granted. This 

notice modifies the notice previously 

published at FR 69(165): 52514–15 

(August 26, 2004). 

DATES: Only written comments and/or 

applications for a license which are 

received by NIH within sixty (60) days 

of this notice will be considered. 

Comments and/or objections filed in 

response to the notices of January 27, 

1993, February 15, 1994 and August 26, 

2004 are not considered responsive to 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 55505 

this notice and will not be treated as 

objections thereto. 

ADDRESSES: Requests for a copy of these 

patent applications, inquiries, comment 

and other materials relating to the 

contemplated license should be directed 

to Susan S. Rucker, Esq., Senior 

Technology Licensing Specialist, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

435–4478; fax: 301/402–0220; or e-mail: 

ruckersu@mail.nih.gov. A signed 

Confidentiality Agreement (CDA) will 

be required to receive copies of the 

patent applications not otherwise 

publicly available. Interested parties 

may obtain copies of U.S. patents and 

pending U.S. patent applications at 

http://www.uspto.gov. European patents 

and patent applications as well as other 

international patent documents are 

available at: http://www.epoline.org. 

Information on Canadian Patents is 

available at: http://patents1.ic.gc.ca/. 

SUPPLEMENTARY INFORMATION: The 

patents and patent applications describe 

and claim compositions and methods 

that incorporate or are derived from the 

molecule known as alpha plateletderived growth factor receptor (aPDGFR). a-PDGFR is also known as 

CD140a/PDGFRA/PDGF2/PDGFR-a. 

PDGFR-a is a type III receptor tyrosine 

kinase characterised by an extracellular 

domain having five IgG-like domains, a 

transmembrane domain and a catalytic 

intracellular domain. Research suggests 

it has autocrine and paracrine signaling 

capability. PDGFRA expression and 

signaling have been linked to 

tumorigenesis and its activity, although 

not always coupled with overexpression, has been implicated in a 

number of cancers including lung 

cancer, ovarian cancer, prostate cancer, 

glioblastoma and melanoma. 

The prospective option to a coexclusive license will be royalty bearing 

and will comply with the terms and 

conditions of 35 U.S.C. 209 and 37 CFR 

404.7. This prospective option to a coexclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license (i.e., a 

completed ‘‘Application for License to 

Public Health Service Inventions’’) in 

the indicated exclusive field of use filed 

in response to this notice will be treated 

as objections to the grant of the 

contemplated option to a co-exclusive 

license. Comments and objections will 

not be made available for public 

inspection and, to the extent permitted 

by law, will not be subject to disclosure 

under the Freedom of Information Act 5 

U.S.C. 552. 

Dated: September 18, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–8083 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of Grants and Training, Citizens 

Corps; Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: DHS, Office of Grants and 

Training, Citizens Corps. 

ACTION: Notice and request for 

comments. 

SUMMARY: Department of Homeland 

Security (DHS), has submitted the 

following information collection to the 

Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the requirements of the 

Paperwork Reduction Act of 1995. The 

submission describes the nature of the 

information collection, the categories of 

respondents, the estimated burden (i.e., 

the time, effort and resources used by 

respondents to respond) and cost, and 

includes the actual data collection 

instruments DHS will use. 

Title: Citizens Corps Individual 

Registration. 

OMB Number: 1660–0078. 

Abstract: This information collection 

will enable Citizens Corps to operate 

effective and efficiently to regularize 

and coordinate activities between 

Citizens Corps and those groups active 

in education, training and coordinating 

volunteers in crime prevention, disaster 

preparedness, mitigation, public health 

and safety issues. 

Affected Public: Individual citizens. 

Number of Respondents: 20,000 per 

year. 

Estimated Time per Respondent: 5 

minutes. 

Estimated Total Annual Burden 

Hours: 1,666.66. 

Frequency of Response: On occasion. 

Comments: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management Budget, 

Attention: Nathan Lesser, Desk Officer, 

Department of Homeland Security/and 

sent via electronic mail to 

oira_submission@omb.eop.gov or faxed 

to (202) 395–6974. Comments must be 

submitted on or before October 23, 

2006. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information or 

copies of the information collection 

should be made to Chief, Records 

Management, DHS, Office of 

Community Preparedness, Karen Marsh, 

810 7th Street, NW., Washington, DC 

20531, Karen.Marsh@dhs.gov, phone 

number (202) 577–9820 and fax number 

(202) 786–9619. 

Dated: September 15, 2006. 

Charlie Church, 

Chief Information Officer, Information and 

Technology Division, Preparedness 

Directorate, Department of Homeland 

Security. 

[FR Doc. 06–7872 Filed 9–21–06; 8:45 am] 

BILLING CODE 4410–10–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of Grants and Training, Citizens 

Corps; Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: DHS, Office of Grants and 

Training, Citizens Corps. 

ACTION: Notice and request for 

comments. 

SUMMARY: Department of Homeland 

Security (DHS), has submitted the 

following information collection to the 

Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the requirements of the 

Paperwork Reduction Act of 1995. The 

submission describes the nature of the 

information collection, the categories of 

respondents, the estimated burden (i.e., 

the time, effort and resources used by 

respondents to respond) and cost, and 

includes the actual data collection 

instruments DHS will use. 

Title: Citizens Corps Council & CERT 

Program Registration. 

OMB Number: 1660–0079. 

Abstract: This information collection 

will enable Citizens Corps to operate 

effectively and efficiently to regularize 

and coordinate activities between 

Citizens Corps and those groups active 

in education, training and coordinating 

volunteers in crime prevention, disaster 

preparedness, mitigation, public health 

and safety issues. 

Affected Public: State and local 

Citizens Corps Councils and CERT 

Programs. 

Number of Respondents: 500 per year. 


sroberts on PROD1PC70 with NOTICES